Fundamental Analysis of BIOCEPT INC(NASDAQ:BIOC) stock

Fundamental Rating

Overall BIOC gets a fundamental rating of 1 out of 10. We evaluated BIOC against 588 industry peers in the Biotechnology industry. BIOC has a bad profitability rating. Also its financial health evaluation is rather negative. BIOC has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year BIOC has reported negative net income.

BIOC had a negative operating cash flow in the past year.

In the past 5 years BIOC always reported negative net income.

BIOC had negative operating cash flow in 4 of the past 5 years.

1.2 Ratios

The Return On Assets of BIOC (-239.73%) is worse than 94.21% of its industry peers.

BIOC has a worse Return On Equity (-18271.38%) than 87.58% of its industry peers.

		Industry Rank	Sector Rank
ROA	-239.73%
ROE	-18271.38%
ROIC	N/A

ROA(3y)-48.71%

ROA(5y)-115.34%

ROE(3y)-148.29%

ROE(5y)-299.94%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BIOC so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

BIOC does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, BIOC has more shares outstanding

The number of shares outstanding for BIOC has been increased compared to 5 years ago.

Compared to 1 year ago, BIOC has a worse debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -26.33, we must say that BIOC is in the distress zone and has some risk of bankruptcy.

The Altman-Z score of BIOC (-26.33) is worse than 92.05% of its industry peers.

BIOC has a Debt/Equity ratio of 4.70. This is a high value indicating a heavy dependency on external financing.

The Debt to Equity ratio of BIOC (4.70) is worse than 86.42% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	4.7
Debt/FCF	N/A
Altman-Z	-26.33

ROIC/WACCN/A

WACC12.08%

2.3 Liquidity

A Current Ratio of 1.81 indicates that BIOC should not have too much problems paying its short term obligations.

The Current ratio of BIOC (1.81) is worse than 82.78% of its industry peers.

A Quick Ratio of 1.70 indicates that BIOC should not have too much problems paying its short term obligations.

With a Quick ratio value of 1.70, BIOC is not doing good in the industry: 81.95% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Current Ratio	1.81
Quick Ratio	1.7

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

BIOC shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -42970.00%.

BIOC shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -54.64%.

Measured over the past years, BIOC shows a very strong growth in Revenue. The Revenue has been growing by 38.52% on average per year.

EPS 1Y (TTM)-42970%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q62.42%

Revenue 1Y (TTM)-54.64%

Revenue growth 3Y67.22%

Revenue growth 5Y38.52%

Revenue growth Q2Q-94.45%

3.2 Future

The Earnings Per Share is expected to grow by 25.57% on average over the next years. This is a very strong growth

BIOC is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -18.32% yearly.

EPS Next Y86.86%

EPS Next 2Y40.26%

EPS Next 3Y25.57%

EPS Next 5YN/A

Revenue Next Year-93.72%

Revenue Next 2Y-59.48%

Revenue Next 3Y-18.32%

Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

BIOC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year BIOC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

BIOC's earnings are expected to grow with 25.57% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y40.26%

EPS Next 3Y25.57%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

BIOC does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

BIOCEPT INC

NASDAQ:BIOC (10/24/2023, 7:22:08 PM)

After market: 0.39 -0.04 (-10.32%)

0.4349

-0.07 (-13.05%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap1.05M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-239.73%
ROE	-18271.38%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover1.27

Health

		Industry Rank	Sector Rank
Debt/Equity	4.7
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	1.81
Quick Ratio	1.7
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)-42970%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y86.86%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-54.64%

Revenue growth 3Y67.22%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

BIOCEPT INC (BIOC)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens